21 Pulmonary Hypertension Clinical Trials in Orlando, FL (2026)

Q: How do I join a clinical trial in Orlando?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Orlando research site will contact you.

Recruiting Pulmonary Hypertension Studies in Orlando

NCT07412002Recruiting

Quality of End-of-Life Care for Children With Cancer

This study examines the role of access to care, patient/family interactions with the healthcare system, and stress in explaining variations in quality of end of life care. The data collected from this...

Orlando, FL2,425 participantsChildren's Oncology Group

View Study Details

NCT06191744Recruiting

Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma

Follicular lymphoma (FL) is the second most common B-cell cancer and the most common type of cancer of lymphocytes. Unfortunately, this disease is incurable with conventional treatment and the disease...

Orlando, FLPHASE31,095 participantsGenmab

View Study Details

NCT06388421Recruiting

DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

This is a prospective, real world, multicenter, registry of patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD) and interstitial lung disease (ILD)....

Orlando, FL900 participantsUnited Therapeutics

View Study Details

NCT06911632Recruiting

Multi-site Study of the Clinical Impact of an AI-assisted Approach to Referring Patients With Interstitial Lung Disease for Diagnostic Evaluation of Pulmonary Hypertension

MOMENTOUS is a multi-center, randomized study to prospectively evaluate the performance of an ECG-based AI device to predict whether participants with interstitial lung disease (ILD) are at high risk ...

Orlando, FLNA900 participantsTempus AI

View Study Details

NCT06481891Recruiting

A Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obstructive and Non-obstructive Hypertrophic Cardiomyopathy

The main purpose of the study is to determine the changes in symptoms and functional limitations in participants with symptomatic hypertrophic cardiomyopathy (HCM) treated with sotagliflozin as compar...

Orlando, FLPHASE3500 participantsLexicon Pharmaceuticals

View Study Details

NCT03801876Recruiting

Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer

This trial studies how well proton beam radiation therapy compared with intensity modulated photon radiotherapy works in treating patients with stage I-IVA esophageal cancer. Proton beam radiation the...

Orlando, FLPHASE3300 participantsNRG Oncology

View Study Details

NCT06564974Recruiting

Registry Study to Observe Long-term Safety of Vamorolone (AGAMREE®) in Patients With Duchenne Muscular Dystrophy-SUMMIT

The goal of this study is to collect additional information on the safety of long-term treatment with AGAMREE® and to explore long-term clinical impact of AGAMREE® on quality of life, as assessed by s...

Orlando, FL250 participantsCatalyst Pharmaceuticals, Inc.

View Study Details

NCT05268289Recruiting

Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V

The overall purpose of this two-part study is to evaluate the efficacy, safety and tolerability of iptacopan (LNP023) in addition to standard of care treatment....

Orlando, FLPHASE2240 participantsNovartis Pharmaceuticals

View Study Details

NCT06649110Recruiting

A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)

A study to learn about the treatment LTP001 in healthy participants (Part A) and in participants with PAH (Part B)...

Orlando, FLPHASE1232 participantsNovartis Pharmaceuticals

View Study Details

NCT06035120Recruiting

An Evaluation of the AeriSeal System for CONVERTing Collateral Ventilation Status in Patients With Severe Emphysema

This is a prospective, open-label, multi-center, single-arm study planned to enroll 200 subjects with heterogeneous emphysema and collateral ventilation (CV) in the target lobe. Subjects will undergo ...

Orlando, FLNA200 participantsPulmonx Corporation

View Study Details

NCT04177914Recruiting

HCRN Endoscopic Versus Shunt Treatment of Hydrocephalus in Infants

Hydrocephalus is a potentially debilitating neurological condition that primarily affects babies under a year of age and has traditionally been treated by inserting a shunt between the brain and the a...

Orlando, FLPHASE3176 participantsUniversity of Utah

View Study Details

NCT05848687Recruiting

TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II

The purpose of this study is to improve upon the TINI study treatment. The study will test the ability of a type of immunotherapy called blinatumomab to clear persistent leukemia. Blinatumomab targets...

Orlando, FLPHASE190 participantsTanja Andrea Gruber

View Study Details

NCT05866419Recruiting

Study of an Intrathecal Port and Catheter System for Subjects With Spinal Muscular Atrophy

The primary objective of the clinical investigation is to demonstrate successful clinical use of the ThecaFlex DRx™ System in delivering nusinersen in subjects with spinal muscular atrophy (SMA). All...

Orlando, FLNA90 participantsAlcyone Therapeutics, Inc

View Study Details

NCT06129240Recruiting

An Open-Label ProSpective MultiCENTer Study to Evaluate Safety and Tolerability of Dry Powder Inhaled Treprostinil in PH

Study LTI-401 is an open-label, multicenter study which will evaluate the safety and tolerability of LIQ861 in subjects who have WHO Group 1 \& 3 PH....

Orlando, FL80 participantsLiquidia Technologies, Inc.

View Study Details

NCT05778188Recruiting

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of RLS-0071 in Newborns With Moderate or Severe Hypoxic-Ischemic Encephalopathy Undergoing Therapeutic Hypothermia

Hypoxic-ischemic encephalopathy (HIE) affects approximately 4,000 to 12,000 persons annually in the United States. Mortality from HIE has been reported up to 60%, with at least 25% of survivors left w...

Orlando, FLPHASE270 participantsReAlta Life Sciences, Inc.

View Study Details

NCT02621944Recruiting

Melatonin as a Neuroprotective Therapy in Neonates With HIE Undergoing Hypothermia

Hypoxic-Ischemic Encephalopathy (HIE) occurs in 20 per 1000 births. Only 47% of neonates treated with the state of the art therapy (induced systemic hypothermia) have normal outcomes. Therefore, other...

Orlando, FLEARLY_PHASE170 participantsUniversity of Florida

View Study Details

NCT04647227Recruiting

SEVENFACT® for Bleeding Events in Hemophilia With Inhibitors

Phase IV multi-center, US-centric, open-label, safety study enrolling participants with Hemophilia A or B with inhibitors, 12 years of age and older, who are either on long term prophylactic treatment...

Orlando, FLPHASE455 participantsAmerican Thrombosis and Hemostasis Network

View Study Details

NCT06624085Recruiting

A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

The purpose of the study is to evaluate glofitamab + gemcitabine + oxaliplatin in participants in the United States, including under-represented racial and ethnic populations, that have relapsed or re...

Orlando, FLPHASE150 participantsHoffmann-La Roche

View Study Details

NCT07096843Recruiting

A Phase 2 Study of Budoprutug in Subjects With Primary Membranous Nephropathy

To evaluate the safety and tolerability of three dose regimens of budoprutug in subjects with PMN...

Orlando, FLPHASE245 participantsClimb Bio, Inc.

View Study Details

NCT06797518Recruiting

Study to Evaluate the Impact of Iptacopan on Top of SOC on Biopsy Changes in Kidneys of Adult Patients With IgAN

A study to investigate the impact of iptacopan treatment on the underlying immunopathology in patients with IgAN by assessing changes in key clinical and molecular markers from baseline to 9 months. T...

Orlando, FLPHASE220 participantsNovartis Pharmaceuticals

View Study Details

NCT07054684Recruiting

Study of BHV-1400 in IgA Nephropathy

The purpose of this study is to determine if BHV-1400 is a safe and tolerable treatment in participants with IgA Nephropathy (IgAN)....

Orlando, FLPHASE120 participantsBiohaven Therapeutics Ltd.

View Study Details

About Pulmonary Hypertension Clinical Trials in Orlando

Pulmonary hypertension is a type of high blood pressure that affects the arteries in the lungs and the right side of the heart. It can lead to heart failure if untreated. Treatment includes vasodilators, endothelin receptor antagonists, and PDE-5 inhibitors.

There are currently 21 pulmonary hypertension clinical trials recruiting participants in Orlando, FL. These studies are seeking a combined 7,808 participants. Research is being sponsored by Children's Oncology Group, Genmab, United Therapeutics and 16 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Pulmonary Hypertension Clinical Trials in Orlando — FAQ

Are there pulmonary hypertension clinical trials in Orlando?

Yes, there are 21 pulmonary hypertension clinical trials currently recruiting in Orlando, FL. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Orlando?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Orlando research site will contact you about next steps.

Are clinical trials in Orlando free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Orlando studies also compensate for your time and travel.

What pulmonary hypertension treatments are being tested?

The 21 active trials in Orlando are testing new therapies including novel drugs, biologics, and treatment approaches for pulmonary hypertension.

Data updated July 18, 2026 from ClinicalTrials.gov